Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 5, 2021 and accepted by EDGAR at Aug 5, 2021, 16:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $82.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $170.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $32.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $64.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-04-01 to 2021-06-30 | $50.2m | us-gaap:GrossProfit |
| Gross profit | 6 months2021-01-01 to 2021-06-30 | $105.8m | us-gaap:GrossProfit |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $3.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $6.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-04-01 to 2021-06-30 | $30.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2021-01-01 to 2021-06-30 | $61.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | $16.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | $37.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $5.4m | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $11.1m | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-01 to 2021-06-30 | −$61.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | −$62.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | $72.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | $88.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | $1.79 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | $2.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | $2.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | $2.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 41,286,853 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 41,251,749 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | $50.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $202.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $318.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $713.7m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $226.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $460.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $253.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-21-010562. Last ingested by Listed: Nov 5, 2026, 12:06 ET. Listed shows no prices and gives no investment advice.